Inovio Pharmaceuticals Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine

Links shared publicly online about this topic.

306
total visits

Inovio Pharmaceuticals Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine

Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term

View full resource at medicalnewstoday.com

Tags: Immune, Vaccination, Infectious Disease, Infection, Cancer, Pharma, Vaccine

Most Recently Shared on May 9, 2011 at 8:23 pm By:

OrganizedWisdom HPV

Inovio Pharmaceuticals Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vac... http://bit.ly/jW3cWo

11 months ago...

Retweet

Favorite

Also Shared By:

MNT Vaccines

MNT Cervical Cancer

MNT Cancer News

Inovio reports long-lasting immune responses with fourth vaccination of VGX-3100 for cervical dysplasia and cancer

news-medical.net — “Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intram” View full resource at news-medical.net

Most Recently Shared on July 15, 2011 at 1:24 pm By:

News-Medical.Net Health News

Malaria News: Inovio reports long-lasting immune responses with fourth vaccination of VGX-3100 for cervical dysp... http://bit.ly/oFGre9

9 months ago...

Retweet

Favorite